(Vienna, October 4, 2021) The number of colorectal cancer (CRC) cases diagnosed fell dramatically by 40% in a year during the COVID-19 pandemic, new research presented today at UEG Week Virtual 2021 has shown1.
The research, which was conducted across multiple hospitals in Spain, compared data from the first year of the COVID-19 pandemic with data from the previous year. Of 1,385 cases of CRC diagnosed over the two-year period, almost two thirds (868 cases, 62.7%) were diagnosed in the pre-pandemic year from 24,860 colonoscopies. By contrast, only 517 cases (37.3%) were diagnosed during the pandemic, which also saw a 27% drop in the number of colonoscopies performed, to 17,337.
Those who were diagnosed with CRC between 15 March 2020 and 28 February 2021 were also older than in the pre-pandemic year, had more frequent symptoms, a greater number of complications and presented at a more advanced disease stage.
Experts say the fall is a consequence of the suspension of screening programmes and the postponement of non-urgent colonoscopy investigations during the pandemic. Fewer cancers were identified by CRC screening in the pandemic period, with just 22 (4.3%) cases found in comparison to 182 (21%) in the pre-pandemic year. During the pandemic, more patients were diagnosed through symptoms (81.2% of diagnoses) compared with the pre-pandemic year (69%).
Dr María José Domper Arnal, from the Service of Digestive Diseases, University Clinic Hospital and the Aragón Health Research Institute (IIS Aragón) in Zaragoza, Spain, and lead author of the study, commented “These are very worrying findings indeed – cases of colorectal cancer undoubtedly went undiagnosed during the pandemic. Not only were there fewer diagnoses, but those diagnosed tended to be at a later stage and suffering from more serious symptoms.”
There was a significant increase in the number of patients being diagnosed with serious complications – a sign of late-stage disease – with an increase in symptoms such as bowel perforation, abscesses, bowel obstruction and bleeding requiring hospital admission. These cases made up 10.6% pre-pandemic and 14.7% during the pandemic. The number of stage IV cancers being diagnosed rose during the pandemic year, with stage IV cases making up 19.9% of cases, in comparison to 15.9% in the previous year.
“Although these figures are across a population of 1.3 million in Spain, it’s highly likely that the same drop in diagnoses would have happened elsewhere across the globe where screening was stopped and surgeries postponed, especially in countries that were heavily impacted by COVID-19”, explained Dr María José Domper Arnal.
“Colorectal cancer is often curable if it’s caught at an early stage. Our concern is that we’re losing the opportunity to diagnose patients at this early stage, and this will have a knock-on effect on patient outcomes and survival. We are likely to see this fall out for years to come.”
CRC (or bowel cancer) is Europe’s second largest cancer killer and the most common digestive cancer. Annually, there are 375,000 newly diagnosed cases in the EU, and it claims the lives of over 170,000 people2. Since the rollout of screening programmes, which now cover over 110 million EU citizens, Europe has observed a steady decline in CRC mortality rates. A recent global study published in The Lancet Gastroenterology and Hepatology demonstrated a correlation between the introduction of screening programmes and a reduction in CRC mortality rates, supporting the benefits of effective screening interventions.
ENDS
Notes to Editors
We kindly ask that a reference to UEG Week is included when communicating any information within this press release.
For further information or to arrange an interview, please contact Luke Paskins on +44 (0) 208 154 6393 or media@ueg.eu
About Dr María José Domper Arnal
Dr María José Domper Arnal is from the Service of Digestive Diseases, University Clinic Hospital and the Aragón Health Research Institute (IIS Aragón) in Zaragoza, Spain.
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European medical specialist and national societies focusing on digestive health.
Our member societies represent more than 30,000 specialists from every field of gastroenterology. Together, we provide services for all healthcare professionals and researchers, in the broad area of digestive health. The role of UEG is to take concerted efforts to learn more about digestive disease by prevention, research, diagnosis, cure and raising awareness of their importance.
To advance the standards of gastroenterological care and knowledge across the world and to reduce the burden of digestive diseases, UEG offers numerous activities and initiatives, including:
- UEG Week: Organising the best international multidisciplinary gastroenterology congress in the world.
- UEG Research: Supporting cooperation and excellence in digestive health research.
- UEG Journal: Delivering clinical information for digestive health with authority.
- UEG Education: Providing learning opportunities in multiple formats.
- Quality of Care: Improving clinical practice to reduce health inequalities across Europe.
- Public Affairs: Acting as the united voice of European Gastroenterology towards the public and policy makers.
Find out more about UEG’s work by visiting www.ueg.eu or contact:
References:
- Impact of the COVID-19 pandemic in the diagnosis and characteristics of colorectal cancer patients, presented at UEG Week Virtual 2021
- https://ueg.eu/files/1028/3806734b256c27e41ec2c6bffa26d9e7.pdf
- https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30345-0/fulltext